ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Clinical Significance of 4L Lymph Node Dissection in Left Lung Cancer.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Dissection of 4L lymph node for left-sided non-small cell lung cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- The prognostic value of 4L lymph node dissection in left-side operable non-small-cell lung cancer: a meta-analysis.Updates in surgery · 2024Pooled it
- Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.Cancer biology & medicine · 2020Trial
- [Etiology, Evaluation and Comprehensive Management of Hoarseness after Lung Cancer Surgery].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Mediastinal lymph node metastasis pattern of subsolid non-small cell lung cancer.Journal of thoracic disease · 2026Article
- 4L lymph node dissection in non-small cell lung cancer: an updated systematic review and subgroup meta-analysis.Journal of thoracic disease · 2025Article
- Recurrence Dynamics of Pathological N2 Non-Small Cell Lung Cancer Based on IASLC Residual Tumor Descriptor.Cancer research and treatment · 2025Article
- Prognostic Implications of Selective Dissection of Left Lower Paratracheal Lymph Nodes in Patients with Left-Sided Non-Small Cell Lung Cancer.Journal of chest surgery · 2024Article
- The prognostic significance of right paratracheal lymph node dissection numbers in right upper lobe non-small cell lung cancer.Updates in surgery · 2024Article
- Development of a nomogram based on the clinicopathological and CT features to predict the survival of primary pulmonary lymphoepithelial carcinoma patients.Respiratory research · 2024Article
- Complete dissection of right paratracheal lymph nodes (stations 2R and 4R) is critical to improve the prognosis of lung cancer patients: A retrospective cohort study.Thoracic cancer · 2023Article
- Prognostic value of L4 lymph node dissection during video-assisted thoracoscopic surgery in patients with left-sided non-small cell lung cancer: a single-center, retrospective cohort study.Translational lung cancer research · 2023Article
- Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm.General thoracic and cardiovascular surgery · 2023Article
- Surgical evaluation of station 4L in patients with lung cancer: the Ugly Duckling.Journal of thoracic disease · 2023Article
- Clinicopathological and survival outcomes of 4L lymph node dissection in left lung adenocarcinoma and squamous cell carcinoma.Frontiers in oncology · 2023Article
- Continuous vagal intraoperative neuromonitoring during video-assisted thoracoscopic surgery for left lung cancer: its efficacy in preventing permanent vocal cord paralysis.Interactive cardiovascular and thoracic surgery · 2022Article
- Mediastinal lymph node evaluation, especially at station 4L, in left upper lobe lung cancer.Journal of thoracic disease · 2022Article
- Prognostic significance of 4R lymph node dissection in patients with right primary non-small cell lung cancer.World journal of surgical oncology · 2022Article
- Clinical significance and outcomes of bilateral and unilateral recurrent laryngeal nerve lymph node dissection in esophageal squamous cell carcinoma: A large-scale retrospective cohort study.Cancer medicine · 2022Article
- Study on the Correlation Between CT Features and Vascular Tumor Thrombus Together With Nerve Invasion in Surgically Resected Lung Adenocarcinoma.Frontiers in surgery · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the prognostic impact of 4L lymph node (LN) dissection in left lung cancer and to analyze the relative risk factors for 4L LN metastasis. PATIENTS AND
methodsWe retrospectively collected data from 657 patients with primary left lung cancer who underwent surgical pulmonary resection from January 2005 to December 2009. One hundred thirty-nine patients underwent 4L LN dissection (4L
resultsThe metastasis rate of station 4L was 20.9%, which was significantly higher than those of station 7 (14.0%; P = .048) and station 9 (9.8%; P < .001). Station 4L metastasis was associated with most other LN station metastases in univariate analysis, but only station 10 LN metastasis was an independent risk factor for 4L LN metastasis (odds ratio, 0.253; 95% CI, 0.109 to 0.588; P = .001) in multivariate logistic analysis. The 4L
conclusionStation 4L LN involvement is not rare in left lung cancer, and dissection of the 4L LN station seems to be associated with a more favorable prognosis as compared with those who did not undergo this dissection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.